Related Experiment Videos
Silent myocardial ischemia. Rationale for management
C J Pepine1, K Coy, C R Lambert
1University of Florida, Gainesville.
Insights
Most coronary artery disease patients experience silent ischemic episodes, which impact prognosis. Therapies like beta-blockers and calcium antagonists can modify these silent events, improving patient outcomes.
Area of Science:
- Cardiology
- Ischemic Heart Disease
Background:
- Silent myocardial ischemia is prevalent in coronary artery disease patients, even those without symptoms.
- Silent ischemia is increasingly recognized as a significant prognostic factor in various patient groups.
Purpose of the Study:
- To review the role of silent ischemia in coronary artery disease prognosis.
- To discuss therapeutic strategies for managing silent ischemia and its associated risks.
Main Methods:
- Review of recent studies on silent ischemia in coronary artery disease.
- Analysis of evidence regarding the impact of various therapies on silent ischemic episodes.
Main Results:
- The majority of ischemic episodes in coronary artery disease patients are silent and correlate with prognosis.
- Nitroglycerin, isosorbide dinitrate, beta-adrenergic blockers, and calcium antagonists can modify silent ischemia.
- Combination therapy with beta-blockers and calcium antagonists appears most effective.
- Angina characteristics do not predict prognosis, unlike certain features of silent ischemia.
Conclusions:
- Silent ischemia significantly influences prognosis in coronary artery disease patients.
- Therapeutic interventions targeting silent ischemia, particularly combination therapy, can modify its frequency and duration.
- Focus should be on improving outcomes in high-risk patients, considering silent ischemia characteristics over angina alone.
Abstract:
Recent studies show that in many coronary artery disease patients with any form of angina, myocardial infarction, or positive exercise tests but no symptoms, most of the ischemic episodes are silent. Furthermore, evidence is building to suggest that in many patient groups, silent ischemia relates to prognosis. Numerous therapies, including nitroglycerin or isosorbide dinitrate, have been shown to modify silent ischemia and its associated risks. Studies indicate that frequency and perhaps duration of silent ischemic episodes can be modified by treatment with beta-adrenergic blockers or calcium antagonists alone or, even more effectively, with a combination of both types of agent. Many ischemic episodes persist, however, when therapy is directed only at reduction of angina. Evidence suggests that some characteristics of silent ischemia predict prognosis, whereas angina characteristics do not. Until additional data about prognosis and the influence of treatment on prognosis are available, the appropriate focus seems to be improvement of outcome in those patients who are at highest risk, rather than only reduction of chest pain.